Update: Positive evaluations in multiple cancer types
Angle’s proprietary cell separation system, Parsortix, can be used to capture and harvest circulating tumour cells from blood, enabling a liquid biopsy. In the near term, Parsortix is being evaluated for use in the pre-surgery triaging of ovarian masses, with a clinical study expected to commence in Q415. H215 has seen positive evaluations of Parsortix in lung, prostate and breast cancer, supporting its potential utility in the multi-billion dollar cancer care market. We value Angle at £96m.ANGLE is a holding company. Through its subsidiares, Co. operates as a medical diagnostic company focusing on the development of products in the fields of cancer diagnostics and foetal health. Co. develops products for use in rare cell diagnostics that enable early identification of an individual's condition for the prevention, treatment, and monitoring of disease. Co.'s principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy (non-invasive cancer diagnostics).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.